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need for studies that examine their relationship to molecular aging  rates.  Toward  this  end,  we  use  recent  epi‐ 



















A number of behavioral lifestyle factors have been 
shown to relate to health, including diet, physical 
activity, moderate alcohol consumption, and 
educational attainment. For instance, diet is a 
modifiable behavior with the potential to mitigate 
chronic disease risk. Various dietary components have 
been reported to influence intermediate risk factors and 
the prevalence of age-related disease outcomes; thus 
there is a growing consensus regarding nutritional 
recommendations for maintaining optimal health. These 
dietary factors include whole grain & dietary fiber [1], 
fish & omega-3 fatty acids [2], and fruits & vegetables 
[3], all of which may be involved in reducing systemic 
inflammation [4]. Further, metabolic health has been 
established as one of the primary mechanisms through 
which diet affects health and disease [5]. Conditions 
such as, insulin resistance, hypercholesterolemia, 
hypertension, hypertryglyceremia, and systemic 
inflammation can be promoted by poor dietary habits 
and often coalesce, influencing a person’s risk of 
atherosclerosis, diabetes mellitus, and stroke [6-8].  
 
In addition to diet, other behaviors such as moderate 
alcohol consumption, increased physical activity, and 
higher educational attainment have all been linked to 
reductions in morbidity and mortality risk [9-16]. Yet, 
despite the strong evidence connecting lifestyle factors 
to health outcomes, it is still unclear whether these 
factors directly influence aging on a molecular level. In 
previous work, leukocyte telomere length (LTL) has 
been used to investigate the influence of lifestyle factors 
on replicative aging in blood [17-21]. A cross-sectional 
study of 2,284 participants from the Nurses’ Health 
Study reported that LTL was associated with BMI, 
waist circumference, and dietary intake of total fat, 
polyunsaturated fatty acids, and fiber [22]. LTL was 


















more physically active [23, 24], as well has those with 
higher levels of education [25].  
 
Another promising measure for investigating the 
dynamics between lifestyle and aging is the molecular 
biomarker known as the “epigenetic clock”. 
Chronological age has been shown to have a profound 
effect on DNA methylation levels [26-34]. As a result, 
several highly accurate epigenetic biomarkers of 
chronological age have been proposed [35-39]. These 
biomarkers use weighted averages of methylation levels 
at specific CpG sites to produce estimates of age (in 
units of years), referred to as "DNA methylation age" 
(DNAm age) or "epigenetic age". Recent studies 
support the idea that these measures are at least passive 
biomarkers of biological age. For instance, the 
epigenetic age of blood has been found to be predictive 
of all-cause mortality [40-43], frailty [44], lung cancer 
[45], and cognitive and physical functioning [46], while 
the blood of the offspring of Italian semi-super-
centenarians (i.e. participants aged 105 or older) was 
shown to have a lower epigenetic age than that of age-
matched controls [47]. Further, the utility of the 
epigenetic clock method using various tissues and 
organs has been demonstrated in applications 
surrounding Alzheimer's disease [48], centenarian status 
[47, 49], development [50], Down syndrome [51], 
frailty [44], HIV infection [52], Huntington's disease 
[53], obesity [54], lifetime stress [55], menopause [56], 
osteoarthritis [57], and Parkinson's disease [58]. 
 
However, relatively little is known about the 
relationship between epigenetic aging rates and lifestyle 
factors, such as diet, alcohol consumption, physical 
activity, and educational attainment. Here, we 
investigate these relationships by leveraging blood 
DNA methylation data from two large epidemiological 
cohorts. In our primary analysis, we use data from older 
women within the Women's Health Initiative (WHI) to 
genetic biomarkers of age that have previously been shown to predict all‐cause mortality, chronic conditions
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examine the relationships between epigenetic age 
acceleration in blood and dietary variables, education, 
alcohol, and exercise. In our secondary analysis, we 
sought to validate the results in the Invecchiare nel 
Chianti (InCHIANTI) Study, which is a population-
based prospective cohort study of residents ages 21 or 
older from two areas in the Chianti region of Tuscany, 
Italy.  
 
Since our study revealed that metabolic syndrome is 
associated with accelerated epigenetic aging, we also 
carried out a post-hoc analysis that evaluated the effect 
of metformin, which is a widely-used medication 






The WHI sample consisted of 4,173 postmenopausal 
women including 2,045 Caucasians, 1,192 African 
Americans, and 717 Hispanics. Chronological age 
ranged from 50-82 years (mean=64, s.d.=7.1). The 
InCHIANTI sample was composed of 402 participants 
from a European (Italian) population, including 178 
men (44%) and 229 women (56%). We used the most 
current cross-sectional wave for this cohort, and at that  
time-point participants ranged in age from 30 to 100 
years (mean=71, s.d.=16). Additional details on 
participant characteristics can be found in the Methods 
and in Table 1. 
 
Dietary and metabolic associations with measures of 
age acceleration 
 
Here we leverage two distinct measures of epigenetic 
age acceleration which are based on different sets of 
CpGs: intrinsic epigenetic age acceleration (IEAA), and 
extrinsic epigenetic age acceleration (EEAA) 
(Methods). Epigenetic age acceleration is broadly 
defined as the epigenetic age left unexplained by 
chronological age, where intrinsic and extrinsic denote 
additional modifications to this concept. In addition to 
adjusting for chronologic age, IEAA also adjusts the 
epigenetic clock for blood cell count estimates, arriving 
at a measure that is unaffected by both variation in 
chronologic age and blood cell composition. EEAA, on 
the other hand, integrates known age-related changes in 
blood cell counts with a blood-based measure of 
epigenetic age [37] before adjusting for chronologic 
age, making EEAA dependent on age-related changes in 
blood cell composition. In essence, IEAA can be 
interpreted as a measure of cell-intrinsic aging and 
EEAA as a measure of immune system aging, where for 
both, a positive value indicates that the epigenetic age 
of an individual (organ or tissue) is higher than 
expected based on their chronological age—or that the 
individual   is  exhibiting  accelerated  epigenetic  aging.  
We find that IEAA is only moderately correlated with 
EEAA (r=0.37), and that measurements on the same 
individuals at different time points (mean difference 3.0 
years between visit dates) showed moderately strong 
correlations (IEAA r=0.70, EEAA r=0.66).  
 
We first used a robust correlation test to relate our two 
measures of epigenetic aging (IEAA and EEAA) to 
select reported dietary exposures, blood nutrient levels, 
cardiometabolic plasma biomarkers, and lifestyle 
factors, designating a Bonferroni-corrected significance 
threshold of α=7x10-4 (Figure 1). The correlation test 
results for specific racial/ethnic groups are presented in 
Supplementary Figure 1 and select marginal 
associations are shown as bar plots in Supplementary 
Figure 2. Pairwise correlations between dietary 
variables, metabolic biomarkers, and lifestyle factors 
are presented in Supplementary Figure 3. 
 
EEAA exhibits weak but statistically significant 
correlations with fish intake (r=-0.07, p=2x10-5), 
alcohol consumption (r=-0.07, p=3x10-5, Supplementary 
Figure 4), plasma levels of mean carotenoids (r=-0.13, 
p=2x10-9), alpha-carotene (r=-0.11, p=9x10-8), beta-
carotene (r=-0.11, p=3x10-7), lutein+zeaxanthin (r=-0.9, 
p=1x10-5), beta-cryptoxanthin (r=-0.11, p=3x10-7), 
gamma-tocopherol (r=0.09, p=9x10-6), triglyceride 
(r=0.7, p=6x10-6), C-reactive protein (CRP, r=0.12, 
p=2x10-10), insulin (r=0.11, p=3x10-12), HDL 
cholesterol (r=-0.09, p=2x10-8), glucose (r=0.06, 
p=2x10-4), systolic blood pressure (r=0.07, p=4x10-6), 
waist-to-hip ratio (WHR, r=0.09, p=2x10-8), BMI 
(r=0.09, p=2x10-8), education (r=-0.10, p=3x10-10), 
income (r=-0.06, p=1x10-4), and exercise (r=-0.07, 
p=2x10-5, Figure 1). In contrast, the intrinsic epigenetic 
aging rate exhibits weaker correlations with dietary 
variables and lifestyle factors: IEAA is only associated 
with BMI (r=0.08, p=1x10-6), and plasma levels of 
gamma-tocopherol (r=0.08, p=2x10-4), CRP (r=0.08, 
p=6x10-5), insulin (r=0.07, p=2x10-5), glucose (r=0.06, 
p=8x10-5), and triglyceride levels (r=0.05, p=5x10-4, 
Figure 1).  
 
Meta-analysis of multivariable linear models link 
epigenetic age acceleration to diet 
 
Associations with EEAA 
We have recently shown that ethnicity relates to 
epigenetic aging rates: e.g. Hispanics have lower levels 
of IEAA compared to other ethnic groups [59]. Given 
the potential for confounding by sociodemographic and 
lifestyle factors, we used Stouffer's method to meta-
analyze multivariate linear models, stratified by 
racial/ethnic group, in order to re-examine the 
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suggestive associations from our marginal correlation 
analysis. After adjusting for sex and dataset (Figure 
2A), we find that lower EEAA is significantly 
associated with greater intake of fish (tmeta=-2.92, 
pmeta=0.003), higher education (tmeta=-4.14, pmeta=3x10-
5), lower BMI (tmeta=4.86, pmeta=1x10-6), and current 

















































find no association for current smoking status, and 
poultry intake, and only a trend toward association with 
physical activity (tmeta=-1.70, pmeta=0.09). In the subset 
of WHI participants with circulating carotenoid 
measurements, we also find that mean carotenoid levels 
are associated with EEAA (tmeta=-4.34, pmeta=1x10-5, 



















































Figure 1. Marginal correlations with epigenetic age acceleration in the WHI. Correlations  (bicor, biweight
midcorrelation) between select variables and the two measures of epigenetic age acceleration are colored according
to  their magnitude with  positive  correlations  in  red,  negative  correlations  in  blue,  and  statistical  significance  (p‐
values)  in  green.  Blood  biomarkers  were measured  from  fasting  plasma  collected  at  baseline.  Food  groups  and
nutrients are inclusive, including all types and all preparation methods, e.g. folic acid includes synthetic and natural,
dairy includes cheese and all types of milk, etc. Variables are adjusted for ethnicity and dataset (BA23 or AS315). 


















































































































      WHI InCHIANTI 
      Count Percent Count Percent 
Ethnic 
American Indian or Alaskan Native 56 1%     
Asian or Pacific Islander 140 3%     
Black or African-American 1277 28%     
Hispanic/Latino 784 17%     
White (not of Hispanic origin) 2196 49%     
Other 37 1%     
WHI data set BA23 2098 47%     AS315 2392 53%     
Sex Male     178 44% Female     229 56% 
Current smoker Nonsmoker 4027 90% 367 90% Smoker 439 10% 40 10% 
Education 
< Primary 43 1% 80 20% 
> Primary 154 3% 154 38% 
> Lower secondary 293 7% 91 22% 
> Upper secondary 2588 58% 62 15% 
> Higher 1393 31% 20 5% 
Physical activity Active 894 20% 329 81% Inactive 3572 80% 78 19% 
      Mean SD Mean SD 
Diet 
Total energy, kcal kcal/day 1641 777 2069 573 
Carbohydrate % kcal 49.0 9.1 52.4 6.9 
Protein % kcal 16.5 3.3 15.8 2.0 
Fat % kcal 34.6 8.1 30.9 5.5 
Red meat serv/day 0.8 0.7 1.1 0.5 
Poultry serv/day 0.4 0.3 0.2 0.2 
Fish serv/day 0.3 0.3 0.2 0.2 
Dairy serv/day 1.6 1.3 2.8 1.8 
Whole grains serv/day 1.2 0.9     
Nuts serv/day 0.2 0.3 0.0 0.1 
Fruits serv/day 1.7 1.3 1.9 0.9 
Vegetables serv/day 1.9 1.3 1.6 0.8 
Alcohol g/day 3.6 9.6 12.7 14.9 
Measurements 
IEAA years 0.0 4.7 0.2 4.6 
EEAA years 0.0 6.0 -0.2 6.5 
C-reactive protein mg/L 5.2 6.6 3.9 7.4 
Insulin mg/dL 57.1 115.3     
Glucose mg/dL 106.3 38.0 93.0 21.3 
Triglycerides mg/dL 146.4 85.6 122.7 81.5 
Total cholesterol mg/dL 228.4 42.7 207.2 36.6 
LDL cholesterol mg/dL 144.9 39.7 125.5 32.1 
HDL cholesterol mg/dL 54.0 14.3 57.6 15.7 
Creatinine mg/dL 0.8 0.2 0.9 0.4 
Systolic blood pressure mmHg 130.0 18.0 129.3 19.8 
Diastolic blood pressure mmHg 75.8 9.4 77.2 10.3 
Waist / hip ratio cm/cm 0.8 0.1 0.9 0.1 
BMI cm/m2 29.7 6.0 27.0 4.3 























Multivariate linear models were used to examine 
whether variations in cardiometabolic biomarkers 
and/or the number of symptoms for metabolic syndrome 
accounted for any of the associations between EEAA 
and lifestyle factors. The inclusion of biomarkers in an 
unstratified model shows that EEAA positively relates 
to CRP (log2, β=0.31, p=3x10-4, Figure 3A, model 3) 
and that this is accompanied by a concomitant 
diminishing in the effect size of BMI (67% decrease in 
coefficient magnitude, Figure 3A, model 2 vs. model 5), 
suggesting that higher CRP may partially explain the 
positive association between BMI and EEAA. When 
metabolic syndrome (MetS) was included in the model, 
results showed that higher EEAA is positively 
associated with the number of metabolic syndrome 
symptoms (β=0.29, p=0.002, Figure 3A, model 4). In 








































tenoid measurements, EEAA was negatively associated 
with mean carotenoid levels (β=-1.10, p=1x10-4) while 
appearing to diminish associations with biomarkers 
(Supplementary Figure 6A, model 5).  
 
Additionally, we find that for the small subset of 
individuals for whom we have EEAA measurements at 
two time points (n=239, mean time interval = 2.7 years), 
increase in BMI (β=0.40, p=0.002) but not initial BMI 
(β=-0.01, p=0.81) is significantly associated with 
increased EEAA (higher follow-up EEAA after 
adjusting for the initial EEAA, dataset, and ethnicity). 
 
Associations with IEAA 
We conducted an analogous meta-analysis of ethnically-
stratified linear models of IEAA and found that lower 























Figure 2. Meta‐analysis of multivariable  linear models of EEAA and  IEAA  in the WHI and  InCHIANTI. EEAA  (panel A) and  IEAA




Figure 3. Multivariate  linear models of EEAA and  IEAA with and without biomarkers in  the WHI. EEAA  (panel A) and  IEAA
(panel B) were  regressed  on  potential  confounding  factors,  fish  and  poultry  intake  and  current  drinker  status,  and  select  biomarkers.
Individual columns list the corresponding coefficient estimates (β) and p‐values (p) for each fitting. Coefficients are colored according to sign
(positive = red, negative = blue) and significance according to magnitude (green). Models 1 through 5 correspond to a minimal model, a model
including  dietary  intake  variables,  a model  including  potential  explanatory  biomarkers,  a model  including  number  of metabolic  syndrome
symptoms and a complete model with all of the variables above, respectively. Models are adjusted for originating dataset (BA23 or AS315). 
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(tmeta=-3.30, pmeta=0.001) and lower BMI (tmeta=4.14, 
pmeta=4x10-5), after adjusting for potential confounders 
(Figure 2B). In the subset of participants with measured 
carotenoids, IEAA was significantly associated with 
mean carotenoid levels (tmeta=-2.47, pmeta=0.01, 
Supplementary Figure 5B). When regressed on clinical 
biomarkers IEAA was significantly associated with 
triglycerides (log2, β=0.40, p=0.02, Figure 3B, model 
3). Their inclusion diminished the association between 
IEAA and BMI (60% decrease in coefficient magnitude, 
Figure 3B, model 2 vs. model 5). Number of metabolic 
syndrome symptoms was also significantly associated 
with IEAA (β=0.27, p=4x10-4, Figure 3B, model 4), and 
diminished the association between IEAA and BMI by 
50%. In the subset of WHI participants with circulating 
carotenoid measurements, we find a trend toward 
association between IEAA and mean carotenoid levels 
(β=-0.40, p=0.07, Supplementary Figure 6B, model 5). 
Finally, in the participants with epigenetic profiling at 
two time points, increase in BMI (β=0.22, p=0.03) but 
not initial BMI (β=-0.22, p=0.44) is significantly 
associated with increased IEAA (higher follow-up 


































Metformin and epigenetic age acceleration 
 
Considering the significant association between our 
measures of epigenetic aging and markers of diabetes, 
we investigated the potential of metformin to modulate 
epigenetic aging. As shown in Supplementary Figure 7, 
women in the No Metformin group were the oldest, 
with mean ages around 65 years, compared to mean 
ages around 64 years for the Metformin Now group and 
62.5 years for the Metformin Future group. Those in the 
No Metformin group also appeared to have a higher 
proportion of college graduates compared to the other 
two groups, whose members tended to have lower 
educational attainment. The two Metformin groups had 
much higher proportions of Non-Hispanic blacks, and 
somewhat higher proportions of Hispanics. As 
expected, women who were prescribed Metformin had 
the highest fasting insulin, fasting glucose, and HOMA-
IR levels, with current Metformin users being the 
highest of all. Similarly, among Metformin users, 
fasting insulin, fasting glucose, and HOMA-IR levels 
were inversely associated with timing of Metformin 
initiation. This suggests that 1) women who had been on 


































aging  and  pro‐aging  effects  in  blood  respectively.  The  two  clocks  symbolize  the  extrinsic
epigenetic clock (enhanced version of the Hannum estimate) and the intrinsic epigenetic clock
(Horvath 2013) which are dependent and independent of blood cell counts, respectively. 
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the most insulin resistant—arguably because they were 
long-time diabetics—and 2) among women who would 
use Metformin in the future, those who would receive 
prescriptions sooner—who may already have pre-
diabetes or diabetes at the time of blood draw—were 
more insulin resistant than women who were prescribed 
Metformin later.  
 
As shown in Supplementary Figure 8, when examining 
the full sample, IEAA and EEAA were highest for 
women in the Metformin Now group, although 
differences between Metformin Now and Metformin 
Future were not significant. Further, the timing of 
Metformin prescription relative to the timing of blood 
draw was not associated with either IEAA or EEAA. 
Overall, these results held for IEAA when restricting 
the sample to only Non-Hispanic whites, Non-Hispanic 
blacks, or women at least 65 years of age. Results for 
EEAA held when restricting the sample to only 
Hispanics, women less than 65 years of age, or those 
with fasting glucose levels under 126 mg/dL. 
Nevertheless, there were no strata in which women in 
the Metformin Now group had significantly lower 
IEAA or EEAA than women in either the No 
Metformin or the Metformin Future group.  
 
Given that Metformin may not be effective for all or that 
not all women prescribed Metformin may comply with 
their physician’s recommendations, we compared future 
Metformin users to current Metformin users who had 
fasting glucose levels under 140 mg/dL (Supplementary 
Figure 9). Similar to Supplementary Figure 8, no 
significant differences were found for the two metformin 
groups, and in most cases those currently on Metformin 
had somewhat higher IEAA and EEAA than those who 
would be prescribed Metformin in the future.  
 
Finally, when using women with repeat blood draws to 
compare the change in IEAA and EEAA for those who 
started Metformin between the two visits to those who 
didn’t (Supplementary Table 1), we find that, while 
those who start Metformin appear to have lower IEAA 
(β=-0.79), the difference is not significant (P=0.46). 
Results for EEAA show very little difference between 
those who start Metformin between first and second 
blood draws, and those who don’t (β=-0.003, P=0.99). 
Given that we only have 11 women who start 
Metformin, our null results, particularly for IEAA, may 
be due to a lack a power. Thus, in moving forward, this 
analysis may be worth revisiting in a randomized 




To our knowledge, this is the first study to examine 
associations between lifestyle factors and measures of 
epigenetic age acceleration in blood. Our main findings 
are summarized graphically in Figure 4. Overall, our 
dietary results are consistent with some of the current 
Dietary Guidelines for Americans [60, 61], reflecting 
potential health benefits associated with higher intake of 
fish, poultry, and fruits and vegetables. The weak 
correlations between dietary factors and epigenetic 
aging rates probably reflect that a relatively large 
proportion of the variance in aging rates (around 40 
percent) is explained by genetic factors [38, 59, 62]. We 
find that education, physical activity, low body mass 
index are associated with a slow extrinsic age 
acceleration both in univariate correlation tests (Figure 
1) and in multivariate regression models (Figure 2A, 
3A). However, consistent with our previous work, 
smoking status was not associated with epigenetic age 
acceleration [45], which highlights that not every poor 
lifestyle choice is associated with an increased 
epigenetic aging effect in blood tissue. 
 
EEAA, inflammation, and metabolic functioning 
 
The age-related changes in immune functioning and 
inflammation are believed to contribute to increased 
susceptibility of a wide range of diseases later in life, 
including diabetes, some cancers, cardiovascular, 
neurodegenerative, auto-immune, and infectious 
diseases [63, 64]. In our analysis, EEAA, a biomarker 
which explicitly incorporates aspects of immune system 
aging such as age-related changes in blood cell counts, 
was associated with cardiometabolic biomarkers, fish, 
fruit, vegetable, and alcohol intake. 
 
Our finding that fish intake was negatively associated 
with EEAA is consistent with prospective studies 
suggesting that fish consumption is protective against 
various age-related diseases [65-67]. The benefits of fish 
intake may be mediated in part through the omega-3 fatty 
acids, eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), which stimulate the synthesis of anti-
inflammatory cytokines [68]. This is further supported by 
our finding that CRP—a well-known marker of 
inflammation—was the most significant explanatory 
biomarker of EEAA. This suggests that one reason higher 
fish consumption may lower EEAA is because it has 
beneficial anti-inflammatory or metabolic effects. The 
consensus between these associations also appears to 
converge on MetS as a potential mediating factor; this 
was further supported by our results showing that the 
number of MetS characteristics significantly relates to 
EEAA. Though CRP is not included in most MetS 
diagnostic criteria, the association between the two has 
been previously established [69]. 
 
We also find that alcohol consumption was negatively 
associated with EEAA even after adjusting for potential 
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confounders such as socioeconomic status; this is 
consistent with prospective studies which have 
identified light to moderate alcohol intake as a 
protective factor against all-cause and CHD-related 
mortality [70, 71] and is supported by a recent 
publication that also found an inverse association 
between epigenetic age and alcohol intake in Caucasian 
and African American individuals (n=656, n=180, 
respectively) [72]. In our study, we find that the 
potential benefits of alcohol consumption are observed 
using a threshold of more than one serving per month, 
though the effect size of this variable was also stable 
when adding weekly and daily intake levels 
(Supplementary Figure 4A-D). The association appears 
to be driven by wine consumption though there is also a 
trend towards association with beer (Supplementary 
Figures 4E-H). This is consistent with other studies 
have suggested that wine may have added benefits 
compared to light alcohol consumption [73]. This 
finding may also be related to the anti-inflammatory 
effects of light alcohol consumption, which are 
associated with decreased circulating levels of 
inflammatory markers such as IL-6 and CRP [74]. 
Alternatively, this may be the result of reverse 
causation, whereby individuals suffering from health 
issues abstain from alcohol consumption [75], though 
interventional studies support a causal protective effect 
of moderated alcohol intake on cardiovascular blood 
biomarkers [76]. 
 
Though EEAA only trended toward association with 
reported fruit and vegetable intake, we find significant 
associations with blood carotenoid levels, which are 
quantitative surrogates of fruit and vegetable intake; this 
is likely a reflection of the bias and inaccuracy of self-
reported diet. This is in agreement with the wide range 
of literature supporting the protective effects of high 
fruit and vegetable intake against age-related diseases 
CHD [77, 78], stroke [79], type-2 diabetes [80], breast 
cancer[81], and all-cause mortality [82]. The association 
between fruit and vegetables with aging of the blood 
immune system may be partially mediated by anti-
inflammatory [83, 84] and cardiometabolic effects, 
however it is interesting to note that the explanatory 
power of mean carotenoid levels remained even after 
including the other explanatory factors into the model, 
suggesting the possibility of independent anti-aging 
mechanisms (Supplementary Figure 6A, model 5). 
 
Our results for EEAA also share similarities with 
previously reported findings showing that LTL relates 
to BMI [22], metabolic factors, vegetable consumption 
[85], and dietary intake of foods high in omega-3 fatty 
acids [86]. This agreement is likely a reflection of the 
shared immunological basis, which is supported by the 
weak negative correlation between EEAA and age-
adjusted LTL. In contrast, IEAA is not significantly 
associated with LTL, supporting the idea that these 
measures represent different aspects of aging. 
 
Intrinsic epigenetic aging and metabolic health 
 
Results showed that BMI has a positive association with 
IEAA (Figure 3B, model 2). The statistically significant 
but weak correlations between BMI and epigenetic age 
acceleration in blood (r<0.10) are much smaller than 
those we recently reported for human liver (r=0.42) 
[54], suggesting that associations between aging 
signatures and risk factors may vary in strength 
depending on the tissue, and may be stronger in 
organs/tissues most affected by the risk. Interestingly, 
IEAA was also associated with number of metabolic 
syndrome characteristics, suggesting a role in tracking 
metabolic aging processes (Figure 3B, model 4). 
 
We did find that reported poultry intake was negatively 
associated with IEAA, even after adjusting for potential 
confounders and explanatory factors (Figure 3B, model 
5). Given the relative inert behavior of IEAA, the 
mechanism by which poultry may affect aging is 
unclear. 
 
Lack of an effect of metformin 
 
Metformin, which is a first-line medication for the 
treatment of type 2 diabetes, has garnered substantial 
interest by aging researchers [87]. The fact that we did 
not detect an anti-aging effect of metformin in our study 
could be due to the following factors: a) it could reflect 
the limitations/biases of an observational study, b) it 
could reflect the limited sample size, or c) that 
metformin does not affect epigenetic aging rates of 
blood tissue. Future randomized controlled trials should 
revisit the question whether metformin affects 
epigenetic aging rates in blood or other tissues. 
 
Generalization to the InCHIANTI  
 
Our results from the InCHIANTI show some validation 
of our findings from the WHI: fish intake was related to 
EEAA, and poultry was related to IEAA. Associations 
with available biomarkers of cardiometabolic health, 
however, were not found to be validated, and in a few 
cases were reversed in directions, within the 
InCHIANTI (data not shown). 
 
The discrepancies between the WHI and InCHIANTI 
cohorts may be due to numerous differences in the 
study population (cultural, demographic, genetic, health 
status, Table 1) and data collection methodology 
(dietary assessment). Despite being younger, on 
average, US participants from the WHI had higher body 
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mass indexes (BMI), and worse metabolic health than 
their Italian counterparts—as indicated by their greater 
prevalence of metabolic syndrome (23% in the WHI 
versus 7.6% in the InCHIANTI). 
 
 The InCHIANTI study is also arguably underpowered 
(n=402) when it comes to detecting the weak associa-
tions with epigenetic age acceleration. According to 
sample size calculations (PASS software), we find that 
n=1820 samples are needed to provide 80% power to 
detect a correlation of r=0.08 at a two-sided significance 
level of α=0.01. Similarly, n=1163 samples are needed 




While our study of the WHI benefits from having a 
relatively large sample size, associations with 
epigenetic aging may not be detectable in smaller 
studies given the weak effect sizes observed here. This 
situation is exacerbated by self-reported lifestyle habits 
which are notorious for bias and inaccuracy, limiting 
their ability to represent true lifestyle habits and 
potentially producing false negative results. Further, as 
evidenced by our results from the ethnic strata and the 
InCHIANTI, studies conducted in different ethnic 
populations may not be entirely consistent due to 
fundamental differences in age, diet, culture, and 
demographics. There were several potential limitations 
to this study, which include the assumption of non-
confounding from unmeasured variables such as 
existing patient co-morbidities and the assumption of 
accuracy and long-term consistency of reported dietary 
habits. This is the first longitudinal study to show that 
an increase in BMI is associated with an increase in 
epigenetic age acceleration but larger longitudinal 
studies will be needed to dissect causal relationships 
between epigenetic aging rates and dietary measures, 
education, exercise, and lifestyle factors. 
 
Conclusions about epigenetic age acceleration 
 
Our large sample size (n>4500) provides sufficient 
statistical power for one of our main conclusions: diet 
has only a weak effect on epigenetic aging rates in 
blood. These findings will be valuable for researchers 
who plan to use epigenetic biomarkers in dietary 
intervention studies. The wide range of associations 
found with EEAA suggest that immune system aging 
may be closely linked to conventional notions of 
metabolic health and may be sensitive to variations in 
environment and lifestyle. In contrast, IEAA has few 
associations, which is consistent with the hypothesis 
that cell-intrinsic aging remains relatively stable, more 
likely being determined by an intrinsic aging or 
developmental process under genetic control. Further, 
using longitudinal data in the WHI, we found that 
change in both EEAA and IEAA are significantly 
associated with change in BMI, suggesting that both 
modes of epigenetic aging may respond to changes in 
lifestyle, at least with respect to change in obesity. 
Overall, our results are consistent with previous 
literature supporting the protective effects of fish, 
poultry and alcohol consumption, exercise, education, 




Estimation of DNA methylation age 
 
DNAm age (also referred to as epigenetic age) was 
calculated from human samples profiled with the 
Illumina Infinium 450K platform, described in detail in 
[38]. Briefly, the epigenetic clock is defined as a 
prediction method of age based on the DNAm levels of 
353 CpGs. Predicted age, referred to as DNAm age, 
correlates with chronological age in sorted cell types 
(CD4+ T cells, monocytes, B cells, glial cells, neurons), 
tissues, and organs, including: whole blood, brain, 
breast, kidney, liver, lung, saliva [38].  
 
We also applied the Hannum measure of DNAm age 
based on 71 CpGs which was developed using DNA 
methylation data from blood [37].  
 
Despite high correlations, DNAm age estimates can 
deviate substantially from chronological age at the 
individual level, and adjusting for age we can arrive at 
measures of epigenetic age acceleration as described in 
the following. 
 
Estimation of Intrinsic and Extrinsic Epigenetic Age 
Acceleration (IEAA, EEAA) 
 
In this article, we consider two measures of epigenetic 
age acceleration. These measures, referred to as intrinsic 
and extrinsic age acceleration only apply to blood. 
IEAA is derived from the Horvath measure of DNAm 
age based on 353 CpGs [38], and is defined as the 
residual resulting from regressing Horvath DNAm age 
on chronological age and estimates of plasmablasts, 
naive and exhausted CD8+ T cells, CD4+ T cells, 
natural killer cells, monocytes, and granulocytes. Thus, 
IEAA is independent of chronological age and most of 
the variation in blood cell composition. IEAA is meant 
to capture cell-intrinsic properties of the aging process 
that exhibits preservation across various cell types and 
organs. 
 
EEAA can be interpreted as an enhanced version of the 
Hannum measure of DNAm age based on 71 CpGs 
[37]. EEAA up-weights the contributions of age related 
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blood cell counts [43]. Specifically, EEAA is defined 
using the following three steps. First, we calculated the 
epigenetic age measure from Hannum et al, which 
already correlated with certain blood cell types [40]. 
Second, we increased the contribution of immune blood 
cell types to the age estimate by forming a weighted 
average of Hannum’s estimate with 3 cell types that are 
known to change with age: naïve (CD45RA+CCR7+) 
cytotoxic T cells, exhausted (CD28-CD45RA-) 
cytotoxic T cells, and plasmablasts using the Klemera 
Doubal approach [88]. The weights used in the 
weighted average are determined by the correlation 
between the respective variable and chronological age. 
The weights were chosen on the basis of the WHI data 
and the same (static) weights were used for all data sets. 
Finally, EEAA was defined as the residual variation 
resulting from a univariate model regressing the 
resulting age estimate on chronological age. Thus, 
EEAA tracks both age related changes in blood cell 
composition and intrinsic epigenetic changes.  
 
In a recent large scale meta-analysis involving over 13 
thousand subjects from 13 cohorts, we have shown that 
both IEAA and EEAA are predictive of mortality, 
independent of chronological age, even after adjusting 
for additional risk factors, and within the racial/ethnic 
groups that we examined (Caucasians, Hispanics, 
African Americans) [43]. 
 
IEAA and EEAA can be obtained from the online 
DNAm age calculator (http://labs.genetics.ucla.edu/ 
horvath/dnamage/), where they are denoted as 
AAHOAdjCellCounts and BioAge4HAStaticAdjAge, 
respectively. 
 
Dietary assessment in the Women's Health Initiative 
(WHI) 
 
Participants were selected from the WHI, a national 
study that began in 1993 and enrolled postmenopausal 
women between the ages of 50-79 years into either 
randomized clinical trials (RCTs) or into an 
observational study [89] (more details available in 
Supplementary Information). Participants completed 
self-administered questionnaires at baseline which 
provided personal information on a wide range of 
topics, including sociodemographic information (age, 
education, race, income), and current health behaviors 
(recreational physical activity, tobacco and alcohol 
exposure, and diet). Participants also visited clinics at 
baseline where certified Clinical Center staff collected 
blood specimens and performed anthropometric 
measurements including weight, height, hip and waist 
circumferences, and systolic and diastolic blood 
pressures; body mass index and waist to hip ratio were 
calculated from these measurements (Table 1). 
Dietary intake levels were assessed at baseline using the 
WHI Food Frequency Questionnaire [90]. Briefly, 
participants were asked to report on dietary habits in the 
past three months, including intake, frequency, and 
portion sizes of foods or food groups, along with 
questions concerning topics such as food preparation 
practices and types of added fats. Nutrient intake levels 
were then estimated from these responses. For current 
drinker, we use the threshold of more than one serving 
equivalent (14g) within the last 28 days. 
 
Estimation of blood cell counts based on DNA 
methylation levels 
 
We estimate blood cell counts using two different 
software tools. First, Houseman's estimation method 
[91], which is based on DNA methylation signatures 
from purified leukocyte samples, was used to estimate 
the proportions of CD8+ T cells, CD4+ T, natural killer, 
B cells, and granulocytes (also known as polymorpho-
nuclear leukocytes). Second, the advanced analysis 
option of the epigenetic clock software [38, 52] was 
used to estimate the percentage of exhausted CD8+ T 
cells (defined as CD28-CD45RA-) and the number 
(count) of naïve CD8+ T cells (defined as 
CD45RA+CCR7+). We and others have shown that the 
estimated blood cell counts have moderately high 
correlations with corresponding flow cytometric 
measures [91, 92]. For example, flow cytometric 
measurements from the MACS study correlate strongly 
with DNA methylation based estimates: r=0.63 for 
CD8+T cells, r=0.77 for CD4+ T cells, r=0.67 for B 
cell, r=0.68 for naïve CD8+ T cell, r=0.86 for naïve 
CD4+ T, and r=0.49 for exhausted CD8+ T cells [92]. 
 
Blood biomarkers and DNA methylation in the WHI 
 
Two separate subsamples were aggregated for our study 
within the WHI (BA23 and AS315). Both had baseline 
blood specimens collected after an overnight fast in 
EDTA tubes and stored at -70C. These samples were 
processed at the WHI core laboratory and select nutrient 
and cardiovascular biomarkers were measured including 
lycopene, alpha- & beta-carotene, alpha- & gamma-
tocopherol, C-reactive protein, triglycerides, total, LDL, 
and HDL cholesterol. 
 
For the first subsample (BA23) consisting of 2098 
samples, DNA methylation levels were measured using 
the Illumina Infinium HumanMethylation450 BeadChip 
at the HudsonAlpha Institute of Biotechnology. This 
platform uses bisulfite conversion to quantify 
methylation levels at 485,577 specific CpG sites 
genome-wide. Samples were prepared according to the 
standard Illumina protocol, and β methylation values 
were calculated from the intensity ratio between 
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methylated and total (methylated and unmethylated) 
probe fluorescence intensities. Methylation data was 
processed as described in [38]. In order to test the 
quality of these array measurements, we perform 
correlation measures with duplicates within this dataset 
and with a "gold" standard which is an average of many 
samples previously collected. Correlation between 
duplicates and with the gold standard were high (r>0.9), 
indicative of high quality measurements. 
 




The Women’s Health Initiative – Epigenetic 
Mechanisms of PM-Mediated CVD (WHI-EMPC, 
AS315) is an ancillary study of epigenetic mechanisms 
underlying associations between ambient particulate 
matter (PM) air pollution and cardiovascular disease 
(CVD) in the Women’s Health Initiative clinical trials 
(CT) cohort. The WHI-EMPC study population is a 
stratified, random sample of 2,200 WHI CT participants 
who were examined between 1993 and 2001; had 
available buffy coat, core analytes, electrocardiograms, 
and ambient concentrations of PM; but were not taking 
anti-arrhythmic medications at the time. As such, WHI-
EMPC is representative of the larger, multiethnic WHI 
CT population from which it was sampled: n = 68,132 
participants aged 50-79 years who were randomized to 
hormone therapy, calcium/vitamin D supplementation, 
and/or dietary modification in 40 U.S. clinical centers at 
the baseline exam (1993-1998) and re-examined in the 
fasting state one, three, six, and nine years later [93]. 
 
Illumina Infinium HumanMethylation450 BeadChip 
data from the Northwestern University Genomics Core 
Facility for WHI-EMPC participants sampled in stages 
1a (800 participants), 1b (1200 participants), and 2 (200 
participants x 2 samples each) was quality controlled 
and batch adjusted. Batch adjustment involved applying 
empirical Bayes methods of adjusting for stage and 
plate as implemented in ComBat [94]. 
 
Dietary assessment in the Invecchiare nel Chianti 
(InCHIANTI) 
 
The InCHIANTI Study is a population-based 
prospective cohort study of residents ages 30 or older 
from two areas in the Chianti region of Tuscany, Italy. 
Data on demographic and lifestyle factors such as 
smoking, years of education, BMI, and physical activity 
were collected during the baseline interview. Physical 
activity in the previous year was categorized as 
sedentary or active. Smoking was categorized into 
current smoker versus former or non-smokers (Table 1). 
In the InCHIANTI study, dietary intake for the past year 
was assessed using a 236 item food frequency 
questionnaire (FFQ) for the European Prospective 
Investigation on Cancer and nutrition (EPIC) study, 
previously validated in the InCHIANTI population [95]. 
The FFQ was administered by a trained interviewer and 
collected information on how frequently (weekly, 
monthly, yearly) each specific food was generally 
consumed. Participants were asked to specify the size of 
the portion usually consumed, in comparison to a range 
of portion that are shown in colored photographs. 
Nutrient data for specific foods were obtained from the 
Food Composition Database for Epidemiological 
Studies in Italy [96]. Dietary information was judged as 
unreliable and excluded from further analysis if 
reported energy intakes were <600 kcal/day or >4,000 
kcal/day and >4,200 kcal/day in women and men, 
respectively.  
 
Blood biomarkers and DNA methylation in the 
InCHIANTI 
 
Sampling and data collection procedures have been 
described elsewhere [97]. Briefly, participants were 
enrolled between 1998 and 2000 and were examined at 
three-year intervals. Serum samples obtained from 
blood collected in evacuated tubes without anti-
coagulant were centrifuged at 2000g for 10 min, and 
stored at -80 °C for measurement of glucose, total, 
LDL, and HDL, cholesterol, triglycerides, CRP, and 
creatinine. DNA methylation was assayed using the 
Illumina Infinium HumanMethylation450 platform for 
n=407 participants with sufficient DNA at both baseline 
(years 1998-2000) and year 9 follow-up visits (2007-
2009). 
 
Assessment of metabolic syndrome 
 
Metabolic syndrome status was assessed using the 
ATPIII NCEP 2004 criteria defined by the presence of 3 
or more of the following characteristics: waist 
circumference >88cm (if male, >102cm), systolic blood 
pressure >130mmHg or diastolic blood pressure 
>85mmHg, fasting plasma glucose >100mg/dL, HDL 
cholesterol <50mg/dL (if male, <40mg/dL), and 
triglycerides >150mg/dL. In regression models, we use 
total number of metabolic syndrome characteristics as 





Biweight midcorrelation, an outlier-robust correlation 
measure, was used to assess marginal linear 
relationships between epigenetic aging measures and 
dietary, cardiometabolic, and socioeconomic factors. To 
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adjust for possible socioeconomic and lifestyle 
confounders, we fit ethnically-stratified multivariable 
linear models adjusting for education, exercise, BMI, 
and current drinker and smoker status. We used 
Stouffer's method to infer the meta-analytic significance 
of each variable over the different ethnic strata using the 
square-root of the sample size as the Z-score weighting 
factor. Specifically for the WHI, the age acceleration 
measures were adjusted for differences in originating 
dataset and within the InCHIANTI the measures were 
adjusted for sex. Models including regression on 
biomarkers, and number of metabolic syndrome 
symptoms were not stratified by ethnicity due to lack of 
coverage for biomarker profiling. Models were 
designed based on common prior knowledge and in 
cases where there was co-linearity between confounding 
variables, choice for adjustment was selected based on 
variable commonality in order to improve comparability 
with other studies, e.g. BMI was chosen over WHR 
because BMI is more commonly measured and reported. 
Variables with skewness >1 were log transformed 
(possibly adding +1 to avoid forming the logarithm of 
zero). Mean carotenoids was computed as the mean 
across standardized measures of lycopene, log2(alpha-
carotene), log2(beta-carotene), log2(lutein + zeaxanthin), 
and log2(beta-cryptoxanthin). Repeat measurements on 
the same individuals were omitted from the analysis. 
 
Metformin analysis 
Prescription medication use was collected at baseline 
for women in both the clinical trial and the 
observational study. Follow-up recording of new 
medication was done at years 1, 3, 6, and 9 for women 
enrolled in clinical trial and at year 3 for those enrolled 
in the observational study. At each of these waves, 
participants were asked to bring in their prescription 
medication bottles and interviewers recorded the 
National Drug Code (NDC), the product name, and 
generic name for each drug. In our analysis, those who 
took prescription drugs that fell under the Therapeutic 
Class Codes (TCCODE), 272500 or 279970 were coded 
as taking Metformin. TCCODE 272500 covered the 
following drugs: Metformin HCL, Metformin ER, 
Fortamet, Glucophage XR, Glucophage, and Riomet; all 
of which were Metformin HCL tablets. TCCODE 
279970 covered the following drugs: Glucovance, 
Glyburide/Metformin HCL, and Metaglip; the first two 
of which were Glyburide and Metformin HCL 
combination tablets, whereas the later is a Glipizide 
Metformin HCL combination tablet. In our study, 
approximately 12% (n=489) of women were reported as 
using Metformin at some time during the study. Women 
were also asked the age at which they started using 
prescribed medication. On average, women in our study 
began metformin use at age 65, with the youngest and 
oldest ages of initiation reported as 41 and 85, 
respectively.  
 
We utilized the reported age of Metformin initiation to 
estimate whether women were using metformin at the 
time of blood draw (when DNAm age was measured), 
and if so, how long they had been on the drug. For those 
women who started using Metformin after the date of 
blood draw, we were also able to calculate the time 
between blood draw and starting on Metformin. Based 
on this, we classified women in to three categories—
“No Metformin” (those who never used Metformin), 
“Metformin Now” (those on Metformin at the time of 
blood draw), and “Metformin Future” (those who began 
Metformin after blood draw). In our sample, 4,073 
women were in the No Metformin group, 139 were in 
the Metformin Now group, and 350 were in the 
Metformin Future group.  
 
Kruskal Wallis tests were used to compare the ages at 
blood draw, education levels, race/ethnicity, fasting 
glucose levels, fasting insulin levels, and degree of 
insulin resistance (measured using the Homeostatic 
Model Assessment of Insulin Resistance--HOMA_IR). 
Biweight midcorrelations were used to examine whether 
these characteristics differed as a function of the timing 
of Metformin initiation among those on Metformin at 
some point during the study. Next Kruskal Wallis tests 
and biweight midcorrelations were used to examine 
whether Metformin group classification and/or the 
timing of Metformin use was associated with IEAA or 
EEAA. For these models, both IEAA and EEAA were 
adjusted for age at blood draw, education, and 
race/ethnicity. These models were run using the full 
sample, and stratifying by age at blood draw (<65 years 
vs. 65+ years), race/ethnicity, and fasting glucose levels 
(<126 mg/dL vs. 126+ mg/dL). Next, a two group 
comparison was made for the full sample and stratifying 
by race/ethnicity between a) 47 women in the 
Metformin Now group for whom Metformin was 
potentially effective (fasting glucose < 140 mg/dL), and 
b) the 350 women in the Metformin Future group. 
Finally, there were 308 women who 1) had IEAA and 
EEAA measured during at least two separate WHI visits 
and 2) were not on Metformin at the time of their first 
blood draw. Of these women, 11 started Metformin in 
between their two blood draws. Based on this, we used 
linear models to compare the change in IEAA and 
EEAA between women who started Metformin between 
their first and second IEAA and EEAA measure and 
those who did not. Models were adjusted for age at first 
blood draw, age at second blood draw, race/ethnicity, 
education, glucose levels at first blood draw, and either 
IEAA or EEAA at first blood draw. 
www.aging‐us.com  432  AGING (Albany NY) 
AUTHOR CONTRIBUTIONS 
 
Austin Quach, Morgan E. Levine, Toshiko Tanaka, 
Brian H. Chen, and Steve Horvath carried out the 
analysis. Devin Absher, Themistocles L. Assimes, Phil 
Tsao, Steve Horvath, Beate Ritz, Luigi Ferrucci, 
Stefania Bandinelli, Eric A. Whitsel, Lifang Hou, 
Andrea Baccerelli, Yun Li, James Stewart contributed 
data. Marian L. Neuhouser, Jeannette M. Beasley, Linda 
Snetselaar, Robert B. Wallace, Ake Lu helped with the 
interpretation of the findings and drafting of the article. 




We would like to acknowledge The WHI Investigators 
listed below: 
Program Office: (National Heart, Lung, and Blood 
Institute, Bethesda, Maryland) Jacques Rossouw, Shari 
Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, 
and Nancy Geller. 
Clinical Coordinating Center: (Fred Hutchinson Cancer 
Research Center, Seattle, WA) Garnet Anderson, Ross 
Prentice, Andrea LaCroix, and Charles Kooperberg. 
Investigators and Academic Centers: (Brigham and 
Women's Hospital, Harvard Medical School, Boston, 
MA) JoAnn E. Manson; (MedStar Health Research 
Institute/Howard University, Washington, DC) Barbara 
V. Howard; (Stanford Prevention Research Center, 
Stanford, CA).  
Marcia L. Stefanick; (The Ohio State University, 
Columbus, OH) Rebecca Jackson; (University of 
Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; 
(University at Buffalo, Buffalo, NY)  
Jean Wactawski-Wende; (University of Florida, 
Gainesville/Jacksonville, FL) Marian Limacher; 
(University of Iowa, Iowa City/Davenport, IA) Robert 
Wallace; (University of Pittsburgh, Pittsburgh, PA) 
Lewis Kuller; (Wake Forest University School of 
Medicine, Winston-Salem, NC) Sally Shumaker. 
Women’s Health Initiative Memory Study: (Wake 
Forest University School of Medicine, Winston-Salem, 
NC) Sally Shumaker. 
 
CONFLICTS OF INTEREST 
 
The Regents of the University of California is the sole 
owner of a provisional patent application directed at the 
invention of measures of epigenetic age acceleration for 
which SH is a named inventor. The other authors 




This WHI study was supported by National Institutes of 
Health NIH/NHLBI 60442456 BAA23 (Assimes, 
Absher, Horvath) and the National Institute of 
Environmental Health Sciences R01ES020836 WHI-
EMPC (Whitsel, Baccarelli, Hou), R01ES021733 
(Baccarelli), and R01ES025225 (Baccarelli). The WHI 
program is funded by the National Heart, Lung, and 
Blood Institute, National Institutes of Health, U.S. 
Department of Health and Human Services through con-
tracts HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, 
HHSN268201100004C, and HHSN271201100004C. 
The authors thank the WHI investigators and staff for 
their dedication, and the study participants for making 
the program possible. A full listing of WHI 




Additional support came from NIH/NIA 
5R01AG042511-02 (Horvath), NIH/NIA 
U34AG051425-01 (Horvath), NIH/NINDS 
T32NS048004 (Levine), and the Burroughs Wellcome 
Fund Inter-school Training Program in Chronic 
Diseases (BWF-CHIP, Quach). The funding bodies 
played no role in the design, the collection, analysis, or 
interpretation of the data. 
 
The InCHIANTI study baseline (1998-2000) was 
supported as a "targeted project" (ICS110.1/RF97.71) 
by the Italian Ministry of Health and in part by the U.S. 
National Institute on Aging (Contracts: 263 MD 9164 







colon  cancer.  Metabolism.  2012;  61:1058–66.  doi: 
10.1016/j.metabol.2012.01.017 
2.   Kris‐Etherton PM, Harris WS, Appel LJ, and American 
Heart  Association.  Nutrition  Committee.  Fish 
consumption,  fish  oil,  omega‐3  fatty  acids,  and 
cardiovascular  disease.  Circulation.  2002;  106:2747–
57. doi: 10.1161/01.CIR.0000038493.65177.94 
3.   van’t Veer P,  Jansen MC, Klerk M, Kok FJ. Fruits and 
vegetables  in  the  prevention  of  cancer  and 
cardiovascular  disease.  Public  Health  Nutr.  2000; 
3:103–07. doi: 10.1017/S1368980000000136 
4.   Giugliano D, Ceriello A, Esposito K. The effects of diet 
on  inflammation:  emphasis  on  the  metabolic 








SC  Jr,  and  International  Diabetes  Federation  Task 
Force on Epidemiology and Prevention, and Hational 
Heart, Lung, and Blood Institute, and American Heart 
Association,  and  World  Heart  Federation,  and 
International  Atherosclerosis  Society,  and 
International  Association  for  the  Study  of  Obesity. 
Harmonizing the metabolic syndrome: a joint interim 
statement  of  the  International  Diabetes  Federation 
Task Force on Epidemiology and Prevention; National 
Heart,  Lung,  and  Blood  Institute;  American  Heart 





RH,  Franklin  BA,  Gordon  DJ,  Krauss  RM,  Savage  PJ, 
Smith SC Jr, Spertus JA, Costa F, and American Heart 
Association,  and  National  Heart,  Lung,  and  Blood 
Institute.  Diagnosis  and  management  of  the 





JB.  Metabolic  syndrome  as  a  precursor  of 
cardiovascular disease  and  type 2 diabetes mellitus. 
Circulation.  2005;  112:3066–72.  doi: 
10.1161/CIRCULATIONAHA.105.539528 
9.   Thun MJ,  Peto  R,  Lopez AD, Monaco  JH, Henley  SJ, 
Heath  CW  Jr,  Doll  R.  Alcohol  consumption  and 
mortality among middle‐aged and elderly U.S. adults. 
N  Engl  J  Med.  1997;  337:1705–14.  doi: 
10.1056/NEJM199712113372401 
10.  Rimm  EB, Williams  P,  Fosher  K,  Criqui M,  Stampfer 
MJ.  Moderate  alcohol  intake  and  lower  risk  of 




of  physical  activity:  the  evidence.  CMAJ.  2006; 
174:801–09. doi: 10.1503/cmaj.051351 
12.  González  MA,  Rodríguez  Artalejo  F,  Calero  JR. 
Relationship  between  socioeconomic  status  and 
ischaemic  heart  disease  in  cohort  and  case‐control 
studies: 1960‐1993. Int J Epidemiol. 1998; 27:350–58. 
doi: 10.1093/ije/27.3.350 
13.  Madsen M,  Andersen  AM,  Christensen  K,  Andersen 
PK,  Osler M.  Does  educational  status  impact  adult 
mortality in Denmark? A twin approach. Am J Epide‐ 
miol. 2010; 172:225–34. doi: 10.1093/aje/kwq072 











17.  Mirabello  L,  Huang  WY,  Wong  JY,  Chatterjee  N, 
Reding D, Crawford ED, De Vivo  I, Hayes RB, Savage 
SA.  The  association  between  leukocyte  telomere 
length  and  cigarette  smoking,  dietary  and  physical 
variables,  and  risk  of  prostate  cancer.  Aging  Cell. 
2009;  8:405–13.  doi:  10.1111/j.1474‐
9726.2009.00485.x 
18.  Boccardi V, Esposito A, Rizzo MR, Marfella R, Barbieri 
M,  Paolisso  G.  Mediterranean  diet,  telomere 
maintenance  and health  status  among  elderly.  PLoS 
One. 2013; 8:e62781. 
doi: 10.1371/journal.pone.0062781 
19.  García‐Calzón  S,  Gea  A,  Razquin  C,  Corella  D, 
Lamuela‐Raventós  RM,  Martínez  JA,  Martínez‐
González  MA,  Zalba  G,  Marti  A.  Longitudinal 
association of telomere  length and obesity  indices  in 
an intervention study with a Mediterranean diet: the 
PREDIMED‐NAVARRA  trial.  Int  J Obes. 2014; 38:177–
82. doi: 10.1038/ijo.2013.68 
20.  Brouilette  SW, Moore  JS, McMahon  AD,  Thompson 
JR,  Ford  I,  Shepherd  J,  Packard  CJ,  Samani  NJ,  and 
West of  Scotland Coronary Prevention  Study Group. 
Telomere  length,  risk of coronary heart disease, and 
statin  treatment  in  the  West  of  Scotland  Primary 
Prevention  Study:  a  nested  case‐control  study. 
Lancet.  2007;  369:107–14.  doi:  10.1016/S0140‐
6736(07)60071‐3 
21.  Kiecolt‐Glaser JK, Epel ES, Belury MA, Andridge R, Lin 
J,  Glaser  R, Malarkey WB,  Hwang  BS,  Blackburn  E. 
Omega‐3  fatty  acids, oxidative  stress,  and  leukocyte 
telomere length: A randomized controlled trial. Brain 
Behav  Immun.  2013;  28:16–24.  doi: 
10.1016/j.bbi.2012.09.004 
22.  Cassidy A, De Vivo  I, Liu Y, Han  J, Prescott  J, Hunter 
DJ,  Rimm  EB.  Associations  between  diet,  lifestyle 
factors,  and  telomere  length  in  women.  Am  J  Clin 
Nutr. 2010; 91:1273–80. 
doi: 10.3945/ajcn.2009.28947 
23.  Latifovic  L,  Peacock  SD,  Massey  TE,  King  WD.  The 
Influence of Alcohol Consumption, Cigarette Smoking, 






The  association  between  physical  activity  in  leisure 
time  and  leukocyte  telomere  length.  Arch  Intern 
Med. 2008; 168:154–58. 
doi: 10.1001/archinternmed.2007.39 
25.  Adler  N,  Pantell  MS,  O’Donovan  A,  Blackburn  E, 
Cawthon R, Koster A, Opresko P, Newman A, Harris 
TB,  Epel  E.  Educational  attainment  and  late  life 
telomere  length  in  the  Health,  Aging  and  Body 
Composition Study. Brain Behav Immun. 2013; 27:15–
21. doi: 10.1016/j.bbi.2012.08.014 
26.  Christensen  BC,  Houseman  EA, Marsit  CJ,  Zheng  S, 
Wrensch MR, Wiemels  JL,  Nelson  HH,  Karagas MR, 
Padbury JF, Bueno R, Sugarbaker DJ, Yeh RF, Wiencke 
JK,  Kelsey  KT.  Aging  and  environmental  exposures 
alter  tissue‐specific  DNA  methylation  dependent 








Beyan  H, Whittaker  P, McCann  OT,  Finer  S,  Valdes 
AM, Leslie RD, Deloukas P, Spector TD. Human aging‐
associated  DNA  hypermethylation  occurs 












on  DNA  methylation  modules  in  human  brain  and 




JE,  Lipska  BK.  DNA  methylation  signatures  in 
development  and  aging  of  the  human  prefrontal 
cortex.  Am  J  Hum  Genet.  2012;  90:260–72.  doi: 
10.1016/j.ajhg.2011.12.020 
32.  Alisch  RS,  Barwick  BG,  Chopra  P, Myrick  LK,  Satten 
GA,  Conneely  KN,  Warren  ST.  Age‐associated  DNA 
methylation  in  pediatric  populations.  Genome  Res. 
2012; 22:623–32. doi: 10.1101/gr.125187.111 
33.  Johansson  A,  Enroth  S,  Gyllensten  U.  Continuous 
Aging of the Human DNA Methylome Throughout the 
Human  Lifespan.  PLoS  One.  2013;  8:e67378.  doi: 
10.1371/journal.pone.0067378 
34.  Day  K,  Waite  LL,  Thalacker‐Mercer  A,  West  A, 












ELOVL2  gene  as  a  new  epigenetic  marker  of  age. 
Aging  Cell.  2012;  11:1132–34.  doi: 
10.1111/acel.12005 
37.  Hannum  G,  Guinney  J,  Zhao  L,  Zhang  L,  Hughes  G, 
Sadda  S,  Klotzle  B,  Bibikova  M,  Fan  JB,  Gao  Y, 
Deconde R, Chen M, Rajapakse I, et al. Genome‐wide 
methylation  profiles  reveal  quantitative  views  of 
human  aging  rates. Mol  Cell.  2013;  49:359–67.  doi: 
10.1016/j.molcel.2012.10.016 
38.  Horvath  S.  DNA  methylation  age  of  human  tissues 
and  cell  types.  Genome  Biol.  2013;  14:R115.  doi: 
10.1186/gb‐2013‐14‐10‐r115 
39.  Lin Q, Weidner CI, Costa IG, Marioni RE, Ferreira MR, 







age of blood predicts all‐cause mortality  in  later  life. 
Genome Biol. 2015; 16:25. doi: 10.1186/s13059‐015‐
0584‐6 
41.  Christiansen  L,  Lenart A,  Tan Q,  Vaupel  JW, Aviv  A, 
McGue  M,  Christensen  K.  DNA  methylation  age  is 
associated  with  mortality  in  a  longitudinal  Danish 
twin  study.  Aging  Cell.  2016; 15:149‐54.  doi: 
10.1111/acel.12421 
42.  Perna  L,  Zhang  Y, Mons  U,  Holleczek  B,  Saum  K‐U, 
Brenner  H.  Epigenetic  age  acceleration  predicts 
www.aging‐us.com  435  AGING (Albany NY) 
cancer,  cardiovascular,  and  all‐cause  mortality  in  a 
German case cohort. Clin Epigenetics. 2016; 8:64. doi: 
10.1186/s13148‐016‐0228‐z 
43.  Chen  BH, Marioni  RE,  Colicino  E,  Peters MJ, Ward‐
Caviness CK, Tsai PC, Roetker NS,  Just AC, Demerath 
EW, Guan W, Bressler J, Fornage M, Studenski S, et al. 





clock  but  not  with  telomere  length  in  a  German 
cohort.  Clin  Epigenetics.  2016;  8:21.  doi: 
10.1186/s13148‐016‐0186‐5 
45.  Levine ME, Hosgood HD, Chen B, Absher D, Assimes T, 
Horvath  S.  DNA  methylation  age  of  blood  predicts 
future  onset  of  lung  cancer  in  the women’s  health 
initiative.  Aging  (Albany  NY).  2015;  7:690–700.  doi: 
10.18632/aging.100809 
46.  Marioni  RE,  Shah  S,  McRae  AF,  Ritchie  SJ,  Muniz‐
Terrera G, Harris  SE, Gibson  J,  Redmond  P,  Cox  SR, 
Pattie  A,  Corley  J,  Taylor  A,  Murphy  L,  et  al.  The 
epigenetic  clock  is  correlated  with  physical  and 
cognitive fitness in the Lothian Birth Cohort 1936. Int 
J  Epidemiol.  2015;  44:1388–96.  doi: 
10.1093/ije/dyu277 







age  of  the  pre‐frontal  cortex  is  associated  with 
neuritic  plaques,  amyloid  load,  and  Alzheimer’s 











51.  Horvath  S,  Garagnani  P,  Bacalini  MG,  Pirazzini  C, 
Salvioli S, Gentilini D, Di Blasio AM, Giuliani C, Tung S, 
Vinters  HV,  Franceschi  C.  Accelerated  epigenetic 
aging  in Down  syndrome. Aging  Cell.  2015;  14:491–
95. doi: 10.1111/acel.12325 
52.  Horvath S, Levine AJ. HIV‐1  infection accelerates age 




Choi  OW,  Tung  S,  Vinters  HV,  et  al.  Huntington’s 
disease accelerates epigenetic aging of human brain 
and  disrupts DNA methylation  levels.  Aging  (Albany 
NY). 2016; 8:1485–512. doi: 10.18632/aging.101005 
54.  Horvath  S,  Erhart W,  Brosch M, Ammerpohl O,  von 
Schönfels  W,  Ahrens  M,  Heits  N,  Bell  JT,  Tsai  PC, 
Spector  TD,  Deloukas  P,  Siebert  R,  Sipos  B,  et  al. 
Obesity accelerates epigenetic aging of human  liver. 
Proc  Natl  Acad  Sci  USA.  2014;  111:15538–43.  doi: 
10.1073/pnas.1412759111 
55.  Zannas  AS,  Arloth  J,  Carrillo‐Roa  T,  Iurato  S,  Röh  S, 
Ressler KJ, Nemeroff CB, Smith AK, Bradley B, Heim C, 
Menke  A,  Lange  JF,  Brückl  T,  et  al.  Lifetime  stress 
accelerates  epigenetic  aging  in  an  urban,  African 
American  cohort:  relevance  of  glucocorticoid 
signaling.  Genome  Biol.  2015;  16:266.  doi: 
10.1186/s13059‐015‐0828‐5 
56.  Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton 
AB,  Ferrucci  L,  Bandinelli  S,  Salfati  E,  Manson  JE, 
Quach  A,  Kusters  CD,  Kuh  D,  Wong  A,  et  al. 
Menopause  accelerates  biological  aging.  Proc  Natl 
Acad  Sci  USA.  2016;  113:9327–32.  doi: 
10.1073/pnas.1604558113 
57.  Vidal  L,  Lopez‐Golan  Y,  Rego‐Perez  I,  Horvath  S, 




58.  Horvath  S,  Ritz  BR.  Increased  epigenetic  age  and 





Jamieson BD,  Sun D,  Li  S,  et  al. An  epigenetic  clock 
analysis  of  race/ethnicity,  sex,  and  coronary  heart 
disease.  Genome  Biol.  2016;  17:171.  doi: 
10.1186/s13059‐016‐1030‐0 
60.  McGuire  S.  US  Department  of  Agriculture  and  US 
Department  of  Health  and Human  Services,  Dietary 
Guidelines  for Americans, 2010. Washington, DC: US 
Government Printing Office,  January 2011. Advances 
in Nutrition: An  International  Review  Journal.  2011; 
23:293‐294. 
61.  Committee DGA. Scientific Report of the 2015 Dietary 
Guidelines  Advisory  Committee.  Washington  (DC): 
www.aging‐us.com  436  AGING (Albany NY) 
USDA  and  US  Department  of  Health  and  Human 
Services. 2015. 
62.  Lu  AT, Hannon  E,  Levine ME, Hao  K,  Crimmins  EM, 
Lunnon K, Kozlenkov A, Mill J, Dracheva S, Horvath S. 
Genetic  variants  near MLST8  and  DHX57  affect  the 





64.  Finch  CE.  Evolution  in  health  and medicine  Sackler 
colloquium:  Evolution  of  the  human  lifespan  and 
diseases  of  aging:  roles  of  infection,  inflammation, 
and nutrition. Proc Natl Acad Sci USA. 2010 (Suppl 1); 
107:1718–24. doi: 10.1073/pnas.0909606106 
65.  Chowdhury  R,  Stevens  S,  Gorman  D,  Pan  A, 
Warnakula  S,  Chowdhury  S,  Ward  H,  Johnson  L, 
Crowe F, Hu FB, Franco OH. Association between fish 
consumption, long chain omega 3 fatty acids, and risk 
of  cerebrovascular  disease:  systematic  review  and 
meta‐analysis.  BMJ.  2012;  345:e6698.  doi: 
10.1136/bmj.e6698 
66.  Zheng J‐S, Hu X‐J, Zhao Y‐M, Yang J, Li D. Intake of fish 
and marine n‐3 polyunsaturated  fatty  acids  and  risk 




LA,  Tucker  KL.  Protective  effects  of  fish  intake  and 
interactive effects of long‐chain polyunsaturated fatty 
acid  intakes  on  hip  bone  mineral  density  in  older 
adults: the Framingham Osteoporosis Study. Am J Clin 





protectins.  J  Immunol.  2005;  174:4345–55.  doi: 
10.4049/jimmunol.174.7.4345 






70.  de  Labry  LO,  Glynn  RJ,  Levenson  MR,  Hermos  JA, 
LoCastro  JS,  Vokonas  PS.  Alcohol  consumption  and 
mortality in an American male population: recovering 
the  U‐shaped  curve‐‐findings  from  the  normative 
Aging  Study.  J  Stud  Alcohol.  1992;  53:25–32.  doi: 
10.15288/jsa.1992.53.25 











73.  Grønbaek  M,  Becker  U,  Johansen  D,  Gottschau  A, 
Schnohr P, Hein HO,  Jensen G, Sørensen TI. Type of 
alcohol  consumed  and  mortality  from  all  causes, 
coronary heart disease, and cancer. Ann  Intern Med. 
2000;  133:411–19.  doi:  10.7326/0003‐4819‐133‐6‐
200009190‐00008 
74.  Volpato  S,  Pahor  M,  Ferrucci  L,  Simonsick  EM, 
Guralnik  JM,  Kritchevsky  SB,  Fellin  R,  Harris  TB. 
Relationship  of  alcohol  intake  with  inflammatory 




75.  Fillmore  KM,  Kerr  WC,  Stockwell  T,  Chikritzhs  T, 
Bostrom  A.  Moderate  alcohol  use  and  reduced 
mortality risk: systematic error in prospective studies. 
Addict  Res  Theory.  2006;  14:101–32.  doi: 
10.1080/16066350500497983 
76.  Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali 
WA.  Effect  of  alcohol  consumption  on  biological 
markers  associated  with  risk  of  coronary  heart 
disease:  systematic  review  and  meta‐analysis  of 
interventional  studies.  BMJ.  2011;  342:d636.  doi: 
10.1136/bmj.d636 
77.  Dauchet  L,  Amouyel  P,  Hercberg  S,  Dallongeville  J. 
Fruit and vegetable consumption and risk of coronary 
heart  disease:  a  meta‐analysis  of  cohort  studies.  J 
Nutr. 2006; 136:2588–93. 
78.  He  FJ,  Nowson  CA,  Lucas  M,  MacGregor  GA. 
Increased  consumption  of  fruit  and  vegetables  is 
related  to  a  reduced  risk of  coronary heart disease: 
meta‐analysis  of  cohort  studies.  J  Hum  Hypertens. 
2007; 21:717–28. doi: 10.1038/sj.jhh.1002212 
79.  He  FJ,  Nowson  CA,  MacGregor  GA.  Fruit  and 
vegetable  consumption  and  stroke: meta‐analysis of 
cohort  studies.  Lancet.  2006;  367:320–26.  doi: 
10.1016/S0140‐6736(06)68069‐0 
80.  Carter P, Gray  LJ,  Troughton  J, Khunti K, Davies MJ. 
Fruit  and  vegetable  intake  and  incidence  of  type  2 
diabetes  mellitus:  systematic  review  and  meta‐
www.aging‐us.com  437  AGING (Albany NY) 




role  of  fruit  and  vegetable  consumption  and  the 




FB.  Fruit  and  vegetable  consumption  and mortality 
from  all  causes,  cardiovascular  disease,  and  cancer: 




Ross  JA,  Hong  C‐P,  Sinaiko  AR.  Fruit  and  vegetable 
consumption  and  its  relation  to  markers  of 
inflammation  and  oxidative  stress  in  adolescents.  J 
Am  Diet  Assoc.  2009;  109:414–21.  doi: 
10.1016/j.jada.2008.11.036 
84.  Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, 
Hu  FB, Willett WC.  Fruit  and  vegetable  intakes,  C‐
reactive protein, and  the metabolic  syndrome. Am  J 
Clin Nutr. 2006; 84:1489–97. 
85.  Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, 
Marlin  R,  Frenda  SJ, Magbanua MJ,  Daubenmier  J, 
Estay  I,  Hills  NK,  Chainani‐Wu  N,  et  al.  Effect  of 
comprehensive  lifestyle  changes  on  telomerase 




86.  Farzaneh‐Far R,  Lin  J,  Epel  ES, Harris WS, Blackburn 
















the  Women’s  Health  Initiative  food  frequency 
questionnaire.  Ann  Epidemiol.  1999;  9:178–87.  doi: 
10.1016/S1047‐2797(98)00055‐6 
91.  Houseman  EA,  Accomando  WP,  Koestler  DC, 
Christensen  BC, Marsit  CJ,  Nelson  HH, Wiencke  JK, 
Kelsey  KT.  DNA  methylation  arrays  as  surrogate 





Jamieson BD,  Sun D,  Li  S,  et  al. An  epigenetic  clock 
analysis  of  race/ethnicity,  sex,  and  coronary  heart 
disease.  Genome  Biol.  2016;  17:171.  doi: 
10.1186/s13059‐016‐1030‐0 
93.  Whitsel EA, Baccarelli A, Hou L. Epigenetic Mechanisms 
of  PM‐Mediated  CVD.    Research  Portfo‐lio  Online 
Reporting  Tools.  National  Institutes  of  Health:  U.S. 





methods.  Biostatistics.  2007;  8:118–27.  doi: 
10.1093/biostatistics/kxj037 
95.  Pisani P, Faggiano F, Krogh V, Palli D, Vineis P, Berrino 
F.  Relative  validity  and  reproducibility  of  a  food 
frequency dietary questionnaire for use  in the Italian 
EPIC  centres.  Int  J  Epidemiol.  1997  (Suppl  1); 
26:S152–60. doi: 10.1093/ije/26.suppl_1.S152 
96.  Bartali  B,  Frongillo  EA,  Bandinelli  S,  Lauretani  F, 
Semba RD, Fried LP, Ferrucci L. Low nutrient intake is 
an essential component of  frailty  in older persons.  J 
Gerontol  A  Biol  Sci Med  Sci.  2006;  61:589–93.  doi: 
10.1093/gerona/61.6.589 
97.  Ferrucci  L,  Bandinelli  S,  Benvenuti  E,  Di  Iorio  A, 
Macchi  C,  Harris  TB,  Guralnik  JM.  Subsystems 
contributing to the decline in ability to walk: bridging 
the gap between epidemiology and geriatric practice 
in  the  InCHIANTI  study.  J  Am  Geriatr  Soc.  2000; 
48:1618–25. 
doi: 10.1111/j.1532‐5415.2000.tb03873.x 
 
 
 
 
 
 
 
 
